Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 554-560

  Buitelaar, Jan K ^a   Kooij, J J Sandra ^b   Ramos Quiroga, J Antoni ^c   Dejonckheere, Joachim ^d   Casas, Miguel ^e   van Oene, Joop C ^f   Schäuble, Barbara ^g   Trott, Goetz Erik ^h  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Program Adult ADHD   (Netherlands)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d SGS Medisearch International NV   (Belgium)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f Janssen Cilag BV Netherlands   (Netherlands)

^g JANSSEN CILAG GMBH   (Germany)

^h Private Practice Aschaffenburg ^*  (Germany)

Author keywords

Adults; Attention deficit hyperactivity disorder; OROS methylphenidate; Response

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OSMOTIC RELEASE ORAL SYSTEM; PATIENT COMPLIANCE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; EDUCATIONAL STATUS; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; OSMOSIS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 79952901836     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.12.016     Document Type: Article

References (35)

1. Andersen S.L., Teicher M.H. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000, 24:137-141.
2. August G.J., Stewart M.A., Holmes C.S. A four-year follow-up of hyperactive boys with and without conduct disorder. Br J Psychiatry 1983, 143:192-198.
3. Barkley R.A., Fischer M., Smallish L., Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002, 111(2):279-289.
4. Biederman J., Faraone S.V., Spencer T.J., Mick E., Monuteaux M.C., Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J Clin Psychiatry 2006, 67(4):524-540.
5. Biederman J., Mick E., Surman C., et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006, 59(9):829-835.
6. Biederman J., Mick E., Spencer T., et al. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr 2006, 11(5):390-396.
7. Buitelaar J.K., Van der Gaag R.J., Swaab-Barneveld H., Kuiper M. Prediction of clinical response to methylphenidate in children with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995, 34(8):1025-1032.
8. Buitelaar J.K., Ramos-Quiroga J.A., Casas M., et al. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2009, 5:457-466.
9. Conners C., Erhart D., Sparrow E. Conners' Adult ADHD Rating Scales (CAARS): Technical Manual 1999, Multi-Health Systems, North Tonawanda, NY.
10. Fallu A., Richard C., Prinzo R., Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin 2006, 22(12):2557-2566.
11. Faraone SV, Biederman J, Spencer T, Mick E, Murray K, Petty C, et al. 2006. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry 163(10): 1720-1729; quiz 1859.
12. Faraone S.V., Perlis R.H., Doyle A.E., et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(11):1313-1323.
13. Faraone S.V., Spencer T., Aleardi M., Pagano C., Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004, 24(1):24-29.
14. Fried R., Petty C.R., Surman C.B., et al. Characterizing impaired driving in adults with attention-deficit/hyperactivity disorder: A controlled study. J Clin Psychiatry 2006, 67(4):567-574.
15. Ghuman J.K., Riddle M.A., Vitiello B., et al. Comorbidity moderates response to methylphenidate in the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 2007, 17(5):563-580.
16. Hechtman L. Predictors of long-term outcome in children with attention-deficit/hyperactivity disorder. Pediatr Clin N Am 1999, 46(5):1039-1052.
17. Kaasinen V., Kemppainen N., Någren K., Helenius H., Kurki T., Rinne J.O. Age-related loss of extrastriatal dopamine D(2)-like receptors in women. J Neurochem 2002, 81(5):1005-1010.
18. Kessler R.C., Adler L., Barkley R., et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006, 163(4):716-723.
19. Kooij J.J., Burger H., Boonstra A.M., Van der Linden P.D., Kalma L.E., Buitelaar J.K. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder randomized placebo controlled double blind cross over trial. Psychol Med 2004, 34(6):973-982.
20. Latimer W.W., August G.J., Newcomb M.D., Realmuto G.M., Hektner J.M., Mathy R.M. Child and familial pathways to academic achievement and behavioral adjustment: a prospective six-year study of children with and without ADHD. J Atten Disord 2003, 7(2):101-116.
21. Li D., Sham P.C., Owen M.J., He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006, 15(14):2276-2284.
22. Medori R., Ramos-Quiroga J.A., Casas M., et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2008, 63(10):981-989.
23. The MTA Cooperative Group Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. The multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999, 56(12):1088-1096.
24. National Institute for Health and Clinical Excellence Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults (Clinical Guideline CG72). Available at: http://www.nice.org.uk/CG72 2008, September, Accessed on.
25. Newcorn J.H. Managing ADHD and comorbidities in adults. J Clin Psychiatry 2009, 70(2):e40.
26. Newcorn J.H., Stein M.A., Cooper K.M. Dose-response characteristics in adolescents with attention-deficit/hyperactivity disorder treated with OROS® methyphenidate in a 4-week, open-label dose-titration study. J Child Adolesc Psychopharmacol 2010, 20(3):187-196.
27. Robinson R.J., Reimherr F.W., Marchant B.K., Faraone S.V., Adler L.A., West S.A. Gender differences in 2 clinical trials of adults with attention-deficit/hyperactivity disorder: a retrospective data analysis. J Clin Psychiatry 2008, 69(2):213-221.
28. Rösler M., Retz W., Retz-Junginger P., et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004, 254(6):365-371.
29. Rösler M., Retz W., Yaqoobi K., Burg E., Retz-Junginger P. Attention deficit/hyperactivity disorder in female offenders: prevalence, psychiatric comorbidity and psychosocial implications. Eur Arch Psychiatry Clin Neurosci 2009, 259(2):98-105.
30. Sonuga-Barke E.J., Coghill D., Markowitz J.S., Swanson J.M., Vandenberghe M., Hatch S.J. Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry 2007, 46(6):701-710.
31. Spencer T., Biederman J., Wilens T., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005, 57(5):456-463.
32. Spencer T., Wilens T., Biederman J., Faraone S.V., Ablon J.S., Lapey K. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995, 52(6):434-443.
33. Stein M.A., McGough J.J. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 2008, 17(2):475-490. xi-xii.
34. van der Oord S., Prins P.J., Oosterlaan J., Emmelkamp P.M. Treatment of attention deficit hyperactivity disorder in children Predictors treatment outcome. Eur Child Adolesc Psychiatry 2008, 17(2):73-81.
35. Volkow N.D., Ding Y.S., Fowler J.S., et al. Dopamine transporters decrease with age. J Nucl Med 1996, 37(4):554-559.